{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:04:41Z","timestamp":1789369481469,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":6028,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1999,3]]},"DOI":"10.1046\/j.1365-2133.1999.02704.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T05:16:03Z","timestamp":1047359763000},"page":"427-431","source":"Crossref","is-referenced-by-count":79,"title":["Long-term follow-up in 51 patients with mycosis fungoides and S\u00e9zary syndrome treated by interferon-alfa"],"prefix":"10.1093","volume":"140","author":[{"family":"JUMBOU","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"N'GUYEN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"TESSIER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"LEGOUX","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"DR\u00c9NO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB1","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.1990.8.1.155","article-title":"Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the S\u00e9zary syndrome","volume":"8","author":"Kohn","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"(Suppl.)","key":"10.1046\/j.1365-2133.1999.02704.x-BIB4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.1990.tb00903.x","article-title":"Interferon alfa-2a in cutaneous T-cell lymphoma","volume":"52","author":"Vegna","year":"1990","journal-title":"Eur J Haematol"},{"issue":"(Suppl. 1)","key":"10.1046\/j.1365-2133.1999.02704.x-BIB5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.1991.tb08119.x","article-title":"Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?","volume":"79","author":"Papa","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB6","first-page":"337","article-title":"Alpha recombinant interferon in the treatment of mycosis fungoides (MF)","volume":"72","author":"Tura","year":"1987","journal-title":"Hematologica"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB7","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1001\/archderm.1990.01670350068009","article-title":"My7 monoclonal antibody for diagnosis of cutaneous T-cell lymphoma","volume":"126","author":"Dr\u00e9no","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB8","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archderm.1993.01680300064009","article-title":"In vitro induction of basal keratinocyte My7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alpha therapy","volume":"129","author":"C\u00e9l\u00e9rier","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2133.1992.tb00672.x","article-title":"Induction of myelo-monocytic My7 antigen (CD13): expression by interferon-\u03b1 in basal cells of cutaneous T-cell lymphomas","volume":"123","author":"Dr\u00e9no","year":"1992","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB10","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0889-8588(18)30056-X","article-title":"Assessing clinical outcomes in cutaneous T-cell-lymphoma","volume":"9","author":"Zacheim","year":"1995","journal-title":"Hematol\/Oncol Clin N Am"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-\u03b12a and etretinate","volume":"125","author":"Dr\u00e9no","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF02505252","article-title":"Incidence and in vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA","volume":"288","author":"Rajam","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/jcp.47.1.43","article-title":"Expression of aminopeptidase-n (CD 13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin","volume":"47","author":"Dixon","year":"1994","journal-title":"J Clin Pathol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/archderm.1997.03890430043007","article-title":"Keratinocyte-lymphocyte interaction in cutaneous T-cell lymphoma: modulation of keratinocyte antigen My7 by a soluble factor produced by T lymphocytes","volume":"133","author":"C\u00e9l\u00e9rier","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0190-9622(91)70036-2","article-title":"Treatment of cutaneous T-cell lymphoma with a combination of low-dose interferon alfa 2a and retinoids","volume":"24","author":"Knobler","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB17","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1365-2133.1988.tb02600.x","article-title":"Treatment of mycosis fungoides with recombinant interferon alfa-2a alone and in combination with etretinate","volume":"118","author":"Thestrup-Pedersen","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-4362.1993.tb01458.x","article-title":"Intra muscular low dose alpha-2b interferon and etretinate for treatment of mycosis fungoides","volume":"32","author":"Altomare","year":"1993","journal-title":"Int J Dermatol"},{"key":"10.1046\/j.1365-2133.1999.02704.x-BIB19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alpha-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2133.1999.02704.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1046\/j.1365-2133.1999.02704.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T19:54:19Z","timestamp":1704311659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/140\/3\/427\/6691516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"URL":"https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02704.x","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,3]]}}}